LA JOLLA, Calif. — Patent fight? What patent fight?

Two of the leading adversaries in the battle to own CRISPR, the powerful gene-editing tool, took the stage together at a genetic medicine conference here, and they couldn’t have been more polite — or more forward-looking.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.

Recommended Stories